Myriad Genetics - Comprehensive Analysis Report

Summary

Myriad Genetics Inc., founded in 1991 and based in Salt Lake City, Utah, is a genetic testing and precision medicine company. Its mission is to improve health and well-being by providing insights into an individual's genetic makeup. The company aims to enable proactive health management and improve disease detection, treatment, and prevention. Myriad Genetics is a personalized medicine company focused on transforming patient lives through molecular diagnostics.

1. Strategic Focus & Objectives

Core Objectives

Myriad's strategy is centered on five key objectives: stabilizing the hereditary cancer market, accelerating growth in oncology, expanding prenatal and mental health offerings, achieving sustained profitable growth, and pursuing international expansion. These aims drive the company's efforts to equip physicians with crucial information for patient care, addressing concerns related to disease likelihood, diagnosis, treatment options, and therapy effectiveness. The primary strategic focus is on the Cancer Care Continuum (CCC) to boost growth and profitability.

Specialization Areas

Myriad Genetics specializes in genetic testing and precision medicine, providing insights that enable proactive health management and improve disease detection, treatment, and prevention. The company serves as a trusted advisor, pioneering molecular diagnostics.

Target Markets

Myriad focuses on providing critical information to physicians to guide healthcare management. Its tests address key questions related to disease likelihood, diagnosis, treatment aggressiveness, and therapy effectiveness, targeting patients who can benefit from genetic insights across various medical conditions.

2. Financial Overview

Funding History

Myriad Genetics has participated in 7 funding rounds. The initial funding round occurred on June 29, 2000. In July 2025, Myriad Genetics obtained a five-year senior secured term loan credit facility providing up to $200 million from OrbiMed, a healthcare investment firm. This consists of $125 million in initial funding, with an option to borrow an additional $75 million until June 30, 2027. The credit facility is set to mature on July 31, 2030. The interest rate is based on the one-month secured overnight financing rate plus 6.50% per year. This credit facility supports the company’s growth strategy and working capital needs, replacing its previous ABL facility.

3. Product Pipeline

Key Products/Services

Myriad Genetics is developing 41 products, primarily focused on cancer, immune system diseases, nervous system diseases, genetic disorders, orthopedic diseases, urologic diseases, nutritional and metabolic diseases, and women's health.

Molecular Residual Disease (MRD) Test: This proprietary, ultra-sensitive test is slated for an early access launch in the first half of 2026. It aims to detect minimal residual disease, potentially guiding treatment decisions.

Precise MRD Assay: This assay is being developed to cater to patients with cancer, academic partners, and biopharma companies, with a commercial launch expected in 2026. It is engineered to meet the needs across different segments.

4. Technology & Innovation

Technology Stack

Myriad Genetics utilizes proprietary technologies to understand the genetic basis of human disease, including its role in onset, progression, and treatment. This knowledge drives the development of new products for predictive medicine, precision medicine, and measuring disease activity.

Restriction Fragment-length Polymorphisms (RFLP): This gene mapping technique was invented by Mark Skolnick and colleagues.

PATHOMIQ's AI-powered platform: Myriad is integrating PATHOMIQ's AI platform for predicting prostate cancer disease outcomes into its Prolaris test, set to launch in early 2026.

Precise MRD test: Myriad's Precise MRD test uses WGS-based ctDNA detection at 0.0001% sensitivity.

5. Leadership & Management

Executive Team

Sam Raha: Appointed as President and Chief Executive Officer in April 2025. Prior to this role, he served as the chief operating officer since joining Myriad in December 2023.

Maggie Ancona: Holds the position of Executive Vice President of Strategy & Transformation, having joined Myriad Genetics in January 2021.

Dale Muzzey, Ph.D.: Serves as the Chief Scientific Officer and has been with the company since April 2014.

Shereen Solaiman: Appointed as Chief People Officer, joining Myriad Genetics in March 2023.

Recent Leadership Changes

Sam Raha was appointed President and CEO in April 2025. Ben Wheeler was promoted to CFO of Myriad Genetics.

6. Competitive Analysis

Major Competitors

Exact Sciences.

Gilead Sciences.

Foundation Medicine.

Guardant Health.

Natera.

Labcorp.

Quest Diagnostics.

BioFire Diagnostics.

23andMe.

Cepheid.

7. Market Analysis

Market Overview

The global genetic testing market was valued at around $15 billion in 2024. It is expected to grow due to advances in precision medicine and increased awareness. The MRD testing market is expected to increase from $1.87 billion in 2024 to $3.54 billion by 2030. Myriad's Cancer Care Continuum focus targets a $170.6 billion market with an 11.3% CAGR through 2030.

8. Strategic Partnerships

jscreen™: Strategic partnership to advance health equity and genetic testing access, combining Myriad's hereditary cancer and reproductive genetics products with jscreen's education and genetic care navigation program.

Intermountain Precision Genomics: Strategic precision oncology collaboration combining germline genetic testing and somatic tumor offering.

ANGLE plc: Collaboration to evaluate the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad's existing tissue-based diagnostic tests.

Lumea Inc.: Agreement to integrate the Prolaris Prostate Cancer Test and MyRisk Hereditary Cancer Test into Lumea's digital pathology platform, BxLink.

9. Operational Insights

Myriad Genetics emphasizes innovation, research and development, and strategic partnerships to sustain its competitive edge. The company leverages over three decades of scientific expertise to deliver actionable genetic insights. Key marketing strategies include physician outreach programs and patient acquisition strategies.

10. Future Outlook

Strategic Roadmap

Myriad's roadmap involves expanding its product pipeline, particularly in oncology and pharmacogenomics. The company is focused on improving test adoption and utilizing real-world evidence. Myriad aims for sustainable growth by developing new tests and optimizing reimbursement strategies.